ADC Therapeutics SA — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
ADC Therapeutics reported Q2 2026 product revenue of $18.6M (flat YoY), with cash of $219.1M (down from $261.3M at year-end 2025). The LOTIS-5 Phase 3 trial met its primary PFS endpoint (HR 0.73, p=0.008) but FDA raised "substantial concerns" regarding the benefit-risk profile due to an imbalance in Grade 5 events (2.9% ZYNLONTA+rituximab vs 1.0% R-GemOx, median age 76 vs 74) in the context of marginal treatment benefit. The company completed LOTIS-7 (100 patients, 90% ORR, 78% CR with glofitamab combination) and is evaluating regulatory pathways. A 17% workforce reduction generated ~$10M annualized cost savings.
Why this rating
LOTIS-5 regulatory setback threatens lead program and near-term growth trajectory; material to $136M market cap but partially offset by strong LOTIS-7 data and cash runway into 2028.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.